-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cooperating with other pharmaceutical companies with technology, drug candidates, and marketing and promotion capabilities has become an important means of facilitating the research and development of new drugs
.
Recently, the pharmaceutical giant Merck has cooperated with four different companies to further expand its oncology product line
1.
Xeris (XeriJect suspension formulation technology)
Xeris (XeriJect suspension formulation technology)
Xeris Biopharma and Merck, headquartered in Chicago, USA, announced that they will cooperate in the development of Xeris' suspension-based formulation technology XeriJect
.
Merck may use XeriJect to combine the technology with undisclosed monoclonal antibodies (mAbs) to "design ultra-high-concentration, ready-to-use formulations
Xeris has just acquired Stonebridge Biopharma and has established various partnerships with large pharmaceutical companies including Tetris Pharmaceuticals
.
The company's CEO Paul R.
2.
Evaxion (immunotherapy EVX-01)
Evaxion (immunotherapy EVX-01)
Evaxion Biotech of Denmark also launched a cooperation with Merck recently
.
The two companies will combine Evaxion's immunotherapy EVX-01 with Merck’s proud checkpoint inhibitor Keytruda (pembrolizumab)
Lars Wegner, MD, CEO of Evaxion, said that promising Phase I/IIa data released this summer indicate that EVX-01 may have the potential to improve treatment prospects for melanoma and other cancers
.
As checkpoint inhibitors are becoming the standard of treatment for these cancer indications, Wegner expressed expectations for the potential clinical benefits of the combination of Keytruda and EVX-01
3.
Daiichi Sankyo and AstraZeneca (Dato-DXd)
Daiichi Sankyo and AstraZeneca (Dato-DXd)
Daiichi Sankyo (Daiichi Sankyo) and AstraZeneca have also recently reached a collaboration with Merck to study the effect of TROP2-directed DXd antibody drug conjugate datopotamab deruxtecan (Dato-DXd) in combination with Keytruda
.
The combination therapy will be evaluated in a phase III study
The use of checkpoint inhibitors such as Keytruda is the current standard of care for these patients in the first-line treatment
.
The two drugs have been tested in pairs before
Reference source: Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio
Reference source: Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio
